Skip to main content

There are no upcoming events at this time.

View All
View Full Calendar See All Updates

Get Email Updates

Energy and Commerce Committee

Letter

Filters
Sort Content By:
Subcommittees
Post Types
Categories

Letter to FDA Requesting Briefing on Coronavirus’ Impact on Drug and Medical Supplies

03.10.2020

Excerpt: “As FDA and our other health agencies respond to this global emergency, we want to ensure that FDA is equipped to maintain its commitment to protecting and promoting public health by addressing potential shortages and minimizing harm for patients,” the bipartisan Committee leaders wrote to Commissioner Hahn.

CLICK HERE to read the letter.

 

Letter

Letter Requesting Briefing on Reporting Requirements for Generic Drugs

03.06.2020

Excerpt: "Since this provision in FDARA was passed into law, we have heard about additional ways that some drug manufacturers may be manipulating the market to harm competition and raise prices.  A complaint filed by the Attorney General of Connecticut and a 44-state coalition in May 2019 details instances where generic manufacturers allegedly exited the market temporarily to suppress competition and fix prices," bipartisan committee leaders wrote.

CLICK HERE to read the letter.

Letter

Letter to Pallone Requesting Hearing on CMS Proposal to Modernize Medicaid

02.05.2020

Excerpt: "We request that the Committee on Energy and Commerce hold a hearing to examine the Healthy Adult Opportunity (HAO) demonstration initiative proposed by the Centers for Medicare and Medicaid Services last week," Walden and Burgess wrote in the letter. "We are concerned that the committee with jurisdiction over the Medicaid program has not examined this proposal, even though the full House will vote on a statement of disapproval tomorrow."

CLICK HERE to read the letter.

Letter

Letter to Pallone and Neal on Medicare Part D Modernization

01.28.2020

Excerpt: "Last May, our committees made progress in negotiating an agreement to modernize the benefit and to deliver essential savings to seniors, but negotiations stopped once H.R. 3 was introduced," Walden and Brady write in the letter. "Now that we know H.R. 3 is going nowhere, Americans need us to return to the negotiation table to deliver on this promise to our seniors this year. It’s time for us to work together to provide real relief to seniors."

CLICK HERE to read the letter.

Letter

Letter to GAO to Review Grant Funding to Combat Opioid Crisis

01.24.2020

Excerpt: "In the interest of ensuring that the funds are directed towards their intended purpose, providing a mechanism where Congress can “see” the development of grants and help direct their constituents to them, and stewarding taxpayer resources in an effective manner, we believe several recent opioid-related legislative packages should be carefully examined to track their destination, assess their impact, and inform our decisions about future efforts," the members wrote in the letter.

CLICK HERE to read the letter to GAO.

Letter

Letter to GAO regarding federal spectrum management

01.24.2020

Excerpt: “Last year, it was clear that the federal spectrum management process broke down,” Pallone and Walden wrote to GAO. “Rather than working through the NTIA as the central repository and manager of federal spectrum, we are concerned that many of the federal agencies with spectrum allocations may have circumvented this statutory process.”

CLICK HERE to read the letter.

Letter

Letter to HHS and DOL on COBRA beneficiaries

01.21.2020

Excerpt: “Many retirees are unexpectedly exposed to out-of-pocket liability for any costs paid under COBRA benefits on or after date of Medicare eligibility and penalties for late enrollment in Medicare” wrote the members. “Some of this risk would be eliminated if COBRA notices addressed the interaction with Medicare, and vice versa. Unfortunately, such information is not required under either Medicare or COBRA, and thus, transparency and clear information about the interaction between the two is lacking.”

CLICK HERE to read the letter.

Letter

Letter to FDA on Lagging Approvals for Complex Generic Drugs

01.17.2020

Excerpt: "We are interested in identifying ways to help reduce the costs of health care for patients, including the costs of prescription drugs. Generic versions of brand-name drugs provide substantial cost savings for patients and third-party payers and account for nine out of ten prescriptions filled in the U.S.," the bipartisan Committee members wrote to FDA.

CLICK HERE to read the letter to FDA.

Letter
Letter